Kancera AB (OSTO:KAN) Other Net Income (Loss) : kr0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Kancera AB Other Net Income (Loss)?

Kancera AB's Other Net Income (Loss) for the three months ended in Sep. 2023 was kr0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2023 was kr0.00 Mil.

Kancera AB Other Net Income (Loss) Historical Data

The historical data trend for Kancera AB's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kancera AB Other Net Income (Loss) Chart

Kancera AB Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Net Income (Loss)

Get a 7-Day Free Trial

Kancera AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Kancera AB Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Kancera AB Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Kancera AB's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Kancera AB (OSTO:KAN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

3EE0:Germany

Address

Karolinska Institutet Science Park, Banvaktsvagen 22, Solna, SWE, 171 48

Website

http://www.kancera.com

Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Kancera AB (OSTO:KAN) Headlines

No Headlines